⚕ GalenOps CRO console
← SITE003 (CAN)

SITE003-0301

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE003 (CAN) (Dr. Okafor) · consented 2023-02-24
Adverse events
7
Serious AEs
1
Open data queries
0
Luna dropout signal
–

Adverse events

moderate assessed 2026-08-18

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-05-03 (study day 56); relationship: N

moderate assessed 2026-08-18

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-08-02 (study day 147); relationship: Y

moderate assessed 2026-08-18

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-08-13 (study day 158); relationship: N

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-08-23 (study day 168); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-09-30 (study day 206); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-10-25 (study day 231); relationship: not assessed

severe serious assessed 2026-08-18

Grade 3 Nausea — outcome: UNKNOWN; onset 2023-10-30 (study day 236); relationship: not assessed; serious criteria: hospitalization

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.